Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Montelukast Sodium 5mg Chewable Formulations
NCT02322671Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (6 arms), sponsored by GSK. Primary endpoint: Composite of plasma pharmacokinetic parameters of montelukast sodium at 24 hours. Started Feb 2015; status: completed.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02322671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322671.